Diagnostics Solutions Strategic Priorities

Roche molecular solutions portfolio GenMark¹ Diagnostics fills the portfolio gap in molecular multiplexing Throughput Oce cobasⓇ LiatⓇ GenMark BOD-G cobas® 5800² cobas® 6800 2021 cobas® 8800 Molecular point-of-care Molecular multiplexing Molecular Molecular high throughput medium throughput 1 GenMark Diagnostics offering is subject to successful closing of the merger agreement dated March 12, 2021; 2 Currently in development and not commercially available Roche 28

View entire presentation